Literature DB >> 20041335

Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer.

José M del Casar1, Guillermo Carreño, Luis O González, Sara Junquera, Salomé González-Reyes, José M González, Miguel Bongera, Antonio M Merino, Francisco J Vizoso.   

Abstract

AIMS: To investigate the expression of matrix metalloproteases (MMPs) and their inhibitors (TIMPs) in patients who develop local recurrence (LR) after mastectomy.
METHODS: We analyzed the expressions of MMP-1, -2, -7, -9, -11, -13, -14, TIMP-1, -2, and -3, using immunohistochemical techniques, in primary tumors from patients without tumoral recurrence (n = 50), patients who developed distant metastasis (n = 50), and from patients who develop LRs (n = 25). LRs of the latter group were also analyzed for MMPs expression. All the patients underwent mastectomy.
RESULTS: Score values for all MMPs and TIMPs were significantly higher in primary tumors of patients with distant metastasis. Primary tumors from patients with LR have lower expressions of MMPs and TIMPs compared with those from patients who developed distant metastasis, and with patients without recurrence for some MMPs. Remarkably, however, primary tumors from patients with LR showed significantly higher percentage of TIMP-1 and 2 expression in stromal cells compared to primary tumors from patients with distant metastasis or primary tumors from patients without tumoral progression. Furthermore, LRs had significantly higher MMP-9 expression than their corresponding primary tumors.
CONCLUSIONS: Our data indicate differences in MMPs/TIMPs expression between primary tumors of patients with LRs and of those with distant metastasis, both after mastectomy for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20041335     DOI: 10.1007/s00432-009-0750-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  81 in total

1.  Breast cancer; five year results: two random series of simple mastectomy with postoperative irradiation versus extended radical mastectomy.

Authors:  S KAAE; H JOHANSEN
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1962-01

2.  Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy.

Authors:  A Talvensaari-Mattila; P Pääkko; G Blanco-Sequeiros; T Turpeenniemi-Hujanen
Journal:  Breast Cancer Res Treat       Date:  2001-01       Impact factor: 4.872

3.  Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer.

Authors:  J Lacour; M Le; E Caceres; T Koszarowski; U Veronesi; C Hill
Journal:  Cancer       Date:  1983-05-15       Impact factor: 6.860

4.  Hypothesis: increasingly intensive locoregional treatment of breast cancer may promote recurrence.

Authors:  A N Papaioannou
Journal:  J Surg Oncol       Date:  1985-09       Impact factor: 3.454

5.  Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival.

Authors:  R Barnes; S Masood; E Barker; A M Rosengard; D L Coggin; T Crowell; C R King; K Porter-Jordan; E S Wargotz; L A Liotta
Journal:  Am J Pathol       Date:  1991-08       Impact factor: 4.307

6.  High levels of TIMP-2 correlate with adverse prognosis in breast cancer.

Authors:  A Remacle; K McCarthy; A Noël; T Maguire; E McDermott; N O'Higgins; J M Foidart; M J Duffy
Journal:  Int J Cancer       Date:  2000-03-20       Impact factor: 7.396

7.  Is it useful to remove internal mammary nodes in operable breast cancer?

Authors:  J Lacour; M G Lê; C Hill; A Kramar; G Contesso; D Sarrazin
Journal:  Eur J Surg Oncol       Date:  1987-08       Impact factor: 4.424

8.  The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology--an overview of findings.

Authors:  B Fisher; C Redmond; E R Fisher
Journal:  Cancer       Date:  1980-08-15       Impact factor: 6.860

9.  Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy.

Authors:  S G Orel; M D Schnall; C M Powell; M G Hochman; L J Solin; B L Fowble; M H Torosian; E F Rosato
Journal:  Radiology       Date:  1995-07       Impact factor: 11.105

10.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1.

Authors:  V Noë; B Fingleton; K Jacobs; H C Crawford; S Vermeulen; W Steelant; E Bruyneel; L M Matrisian; M Mareel
Journal:  J Cell Sci       Date:  2001-01       Impact factor: 5.285

View more
  5 in total

Review 1.  A new paradigm for mechanobiological mechanisms in tumor metastasis.

Authors:  Peter A Torzilli; Jonathan W Bourne; Tessa Cigler; C Theresa Vincent
Journal:  Semin Cancer Biol       Date:  2012-05-18       Impact factor: 15.707

Review 2.  Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.

Authors:  Elin Hadler-Olsen; Jan-Olof Winberg; Lars Uhlin-Hansen
Journal:  Tumour Biol       Date:  2013-05-17

3.  Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer.

Authors:  Ga-Eon Kim; Ji Shin Lee; Yoo-Duk Choi; Kyung-Hwa Lee; Jae Hyuk Lee; Jong Hee Nam; Chan Choi; Sung Sun Kim; Min Ho Park; Jung Han Yoon; Sun-Seog Kweon
Journal:  BMC Cancer       Date:  2014-12-16       Impact factor: 4.430

Review 4.  Collagen as a double-edged sword in tumor progression.

Authors:  Min Fang; Jingping Yuan; Chunwei Peng; Yan Li
Journal:  Tumour Biol       Date:  2013-12-15

5.  Ionizing radiation-mediated premature senescence and paracrine interactions with cancer cells enhance the expression of syndecan 1 in human breast stromal fibroblasts: the role of TGF-β.

Authors:  Eleni Liakou; Eleni Mavrogonatou; Harris Pratsinis; Sophia Rizou; Konstantinos Evangelou; Petros N Panagiotou; Nikos K Karamanos; Vassilis G Gorgoulis; Dimitris Kletsas
Journal:  Aging (Albany NY)       Date:  2016-08       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.